There was a trend approaching significance suggesting a lower rate of acute rejection in Treg-treated patients compared with the Reference cohort (0% vs. 21.1%), despite there being a lower immunosuppression load and no induction therapy ( Figure 3A ).
← all excerpts
Feasibility, long-term safety, and immune monitoring of regulatory T cell therapy in living donor kidney transplant recipients.
1
—
—